Szpital Uniwersytecki w Krakowie Report issue

Academic/Hospital Phase 3

Organization Overview

First Clinical Trial
2008
NCT00864851
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2010

Timeline

NOW
  • Now

Alternative names

University Hospital in Krakow

Active Ingredients

Drugs in Phase 3 Trials (1)

agalsidase alfa (Replagal) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Fabry Disease (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 1